版本:
中国

BRIEF-Shire granted EU approval for pancreatic cancer combination therapy

Oct 18 Shire Plc

* Granted eu marketing authorization of onivyde, in combination with 5-fluorouracil (5-fu) and leucovorin (lv),for treatment of metastatic adenocarcinoma of pancreas in adult patients who have progressed following gemcitabine-based therapy Source text for Eikon: Further company coverage: (Reporting By UK Bureau)

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐